Conference/Events
|
Life Sciences &… Life Sciences & MedTech Virtual Forum to be held on March 22-23. ShowHide Related Items >><< - 03/22/22
- Exagen receives subpoena in Feb. from DOJ, says 'fully cooperating'
- 10/27/21
- Exagen expands coverage with Inland Empire Health Plan
- 10/25/21
- Exagen announces $27.2M debt refinancing
- 02/28/22
- West Pharmaceutical names Eric Green as Chair of Board
- 01/25/22
- West Pharmaceutical enters supply, technology agreement with Corning
- 02/23/22
- Teleflex: FDA clears expanded indication for specialty catheters
- 03/14/22
- Sodexo announces national GPO agreement with Premier
- 10/26/21
- Premier, Resilinc announce supply chain transparency collaboration
- 12/15/21
- NextGen Healthcare CMO Betty Rabinowitz to retire, Robert Murry to succeed
- 10/28/21
- NextGen Healthcare announces $60M share repurchase program
- 10/05/21
- Proxy firms ISS and Glass Lewis support NextGen Healthcare director nominees
- 09/28/21
- NextGen Healthcare provides presentation amid proxy fight against Sheldon Razin
MRVI Maravai Lifesciences - 02/25/22
- Maravai Lifesciences up 10% after Reuters says rejected $42 per share bid
- 01/28/22
- Maravai Lifesciences acquires MyChem for $240M in cash
- 12/14/21
- Maravai Lifesciences added to the Nasdaq Biotechnology Index
- 11/29/21
- Codex DNA announces commercial availability of BioXp mRNA synthesis kits
- 02/24/22
- LeMaitre announces $20M share repurchase authorization
- 03/08/22
- Invacare sees FY22 adjusted EBITDA, free cash fow up from FY21
- 12/01/21
- Invacare realigns EMEA, Asia Pacific businesses
- 11/30/21
- FDA posts warning letter sent to Invacare on November 18
- 11/05/21
- NetScout to replace Invacare in S&P 600 at open on 11/5
- 03/04/22
- Inogen names Kristin Caltrider as CFO, succeeding Mike Sergesketter
- 02/24/22
- Inogen sees Q1 revenue similar to Q4, sees FY22 revenue up mid-single digits
- 12/30/21
- Inogen appoints Elizabeth Mora as board chairperson
- 12/13/21
- Inogen announces Sergesketter as Interim Chief Financial Officer
- 03/07/22
- Evolent Health expects to continue provision of services to Cook County Health
- 02/24/22
- Evolent Health rises 16.3%
- 10/15/21
- Evolent Health up 2% as Dealreporter speculates on deal fit with Walgreens
- 09/29/21
- Evolent Health trading resumes
- 01/03/22
- Enzo Biochem appoints CEO Hamid Erfanian to board
- 10/25/21
- Radoff issues letter to Enzo independent directors regarding shareholder unrest
- 10/21/21
- Enzo Biochem expands GoTestMeNow online portal
- 10/18/21
- Enzo Biochem appoints Hamid Erfanian as Chief Executive Officer
EBS Emergent BioSolutions - 03/11/22
- Emergent BioSolutions initiates Phase 1 study of SIAN
- 02/18/22
- FDA says added four lots of AstraZeneca COVID vaccine acceptable for export
- 02/11/22
- Emergent BioSolutions 'disappointed' in appeals ruling in Narcan case with Teva
- 01/14/22
- Emergent BioSolutions founder and executive chairman, Fuad El-Hibri, to retire
- 01/12/22
- Castle Biosciences publishes sequencing panel study for melanoma analysis
- 11/24/21
- Castle presents data backing clinical utility of DecisionDx portfolio
- 11/19/21
- Castle Biosciences announces publication of DecisionDx-Melanoma data
- 10/25/21
- Castle Biosciences acquiring Pittsburgh Life Science Greenhouse's Cernostics
- 03/18/22
- BioLife Solutions receives Nasdaq notice of noncompliance for delayed 10-K
- 03/17/22
- BioLife Solutions announces additional delay in filing Form 10-K
- 11/04/21
- BioLife Solutions names Troy Wichterman as CFO, Roderick de Greef as COO
- 01/06/22
- Azenta names Matthew McManus as COO
- 11/16/21
- Brooks Automation to change name to Azenta, effective December 1
- 02/15/22
- Avantor chairman Rajiv Gupta to retire
- 02/11/22
- Avantor starts construction on new distribution center in Ireland
- 11/15/21
- Third Point buys Alight, exits Uber in Q3
- 12/15/21
- Avanos announces $30M share repurchase program
- 12/13/21
- Avanos to acquire OrthogenRx, Inc. for $160M
- 01/12/22
- AngioDynamics CEO buys $228K in common stock
- 03/09/22 Citi
- Agiliti price target lowered to $25 from $28 at Citi
- 01/10/22 Citi
- Agiliti assumed with a Buy at Citi
- 08/16/21 Citi
- Citi says Agiliti selloff overdone, boosts target to $22
- 05/26/21 BMO Capital
- Agiliti price target raised to $26 from $18 at BMO Capital
- 02/25/22 Piper Sandler
- Amwell price target lowered to $7 from $12 at Piper Sandler
- 02/11/22 Goldman Sachs
- Amwell initiated with a Neutral at Goldman Sachs
- 12/01/21 Jefferies
- Amwell initiated with a Hold at Jefferies
- 11/22/21 Piper Sandler
- Piper remains buyer of Amwell despite chat supporting below consensus FY22 view
- 01/07/22 Canaccord
- AngioDynamics price target lowered to $34 from $37 at Canaccord
- 10/15/21
- Fly Intel: Top five analyst upgrades
- 10/15/21 Canaccord
- AngioDynamics upgraded to Buy at Canaccord on future growth clarity
- 10/15/21 Canaccord
- AngioDynamics upgraded to Buy from Hold at Canaccord
- 02/24/22 KeyBanc
- Avanos price target lowered to $41 from $47 at KeyBanc
- 08/04/21 KeyBanc
- Avanos price target lowered to $47 from $55 at KeyBanc
- 08/04/21 Stephens
- Avanos downgraded to Equal Weight from Overweight at Stephens
- 02/07/22 Raymond James
- Avantor price target lowered to $43 from $47 at Raymond James
- 02/07/22 Baird
- Avantor price target lowered to $43 from $44 at Baird
- 02/07/22 Barclays
- Avantor price target raised to $44 from $41 at Barclays
- 01/27/22 Barclays
- Avantor price target lowered to $41 from $48 at Barclays
- 03/21/22 Evercore ISI
- Azenta initiated with an Outperform at Evercore ISI
- 02/09/22 Needham
- Azenta price target lowered to $115 from $155 at Needham
- 11/17/21 Stifel
- Brooks Automation price target raised to $149 from $134 at Stifel
- 11/17/21 Stephens
- Brooks Automation price target raised to $137 from $130 at Stephens
- 03/02/22 B. Riley
- BioLife Solutions price target lowered to $48 from $67 at B. Riley
- 01/03/22 Stephens
- Wendy's, Kirby and Vizio among Stephens' 2022 Best Ideas
- 12/31/21 Northland
- BioLife Solutions named a top pick for 2022 at Northland
- 10/19/21 B. Riley
- BioLife Solutions transferred with Buy, $61 target at B. Riley
- 03/01/22 Lake Street
- Castle Biosciences price target lowered to $63 from $94 at Lake Street
- 03/01/22 Baird
- Castle Biosciences price target lowered to $60 from $82 at Baird
- 01/06/22 Stephens
- Stephens starts skin cancer test leader Castle Biosciences at Overweight
- 01/06/22 Stephens
- Castle Biosciences initiated with an Overweight at Stephens
EBS Emergent BioSolutions - 01/20/22 Cantor Fitzgerald
- Emergent BioSolutions price target raised to $55 from $50 at Cantor Fitzgerald
- 01/20/22 Benchmark
- Emergent BioSolutions upgraded to Buy from Hold at Benchmark
- 12/27/21 Cowen
- Emergent's Narcan sales under immediate threat, says Cowen
- 11/10/21 Chardan
- Emergent BioSolutions price target lowered to $75 from $92 at Chardan
- 03/08/22 Cowen
- Evolent Health remains top pick after meeting with management, says Cowen
- 03/07/22 Piper Sandler
- Evolent Health news removes $82M overhang, says Piper Sandler
- 03/04/22 Piper Sandler
- Bright Health expansion big revenue opportunity for Evolent, says Piper
- 02/24/22 Piper Sandler
- Evolent Health price target lowered to $32 from $36 at Piper Sandler
- 09/09/21 Raymond James
- ICU Medical price target raised to $286 from $220 at Raymond James
- 12/09/21 Needham
- Inogen upgraded to Buy from Hold at Needham
- 12/09/21 Needham
- Inogen upgraded to Buy from Hold at Needham
- 11/02/21
- Fly Intel: Top five analyst upgrades
- 11/02/21 JPMorgan
- Inogen upgraded to Neutral with risks priced in at JPMorgan
- 09/10/21 Needham
- Invacare price target lowered to $8 from $17 at Needham
- 08/19/21 Oppenheimer
- Invacare initiated with an Outperform at Oppenheimer
- 02/25/22 Barrington
- LeMaitre price target lowered to $54 from $62 at Barrington
- 09/16/21
- Fly Intel: Top five analyst initiations
- 09/16/21 Jefferies
- Jefferies starts LeMaitre at Buy on ArteGraft upside potential
- 09/16/21 Jefferies
- LeMaitre initiated with a Buy at Jefferies
MRVI Maravai Lifesciences - 02/28/22 William Blair
- Maravai buyout price would need to be well into $50s, says William Blair
- 02/24/22 Baird
- Maravai Lifesciences price target lowered to $48 from $60 at Baird
- 10/01/21 Morgan Stanley
- Maravai selloff on Merck's molnupiravir data overdone, says Morgan Stanley
- 08/11/21 Credit Suisse
- Maravai Lifesciences price target raised to $54 from $44 at Credit Suisse
- 01/26/22 Piper Sandler
- NextGen Healthcare price target raised to $24 from $23 at Piper Sandler
- 01/06/22 SVB Leerink
- SVB Leerink upgrades NextGen Healthcare to Outperform with $22 price target
- 01/06/22 SVB Leerink
- NextGen Healthcare upgraded to Outperform from Market Perform at SVB Leerink
- 01/05/22 Piper Sandler
- NextGen Healthcare named a 2022 top pick at Piper Sandler
- 11/18/21 Barclays
- Premier price target raised to $36 from $34 at Barclays
- 11/03/21 Piper Sandler
- Premier price target raised to $39 from $31 at Piper Sandler
- 05/28/21
- Fly Intel: Top five analyst downgrades
- 05/28/21 Barclays
- Barclays double downgrades Premier with multiple expansion less likely
- 02/24/22 Piper Sandler
- Teleflex price target raised to $335 from $320 at Piper Sandler
- 01/21/22 Piper Sandler
- Teleflex price target lowered to $320 from $325 at Piper Sandler
- 01/07/22 Morgan Stanley
- Teleflex cut to Equal Weight at Morgan Stanley on near-term UroLift caution
- 01/07/22 Morgan Stanley
- Teleflex downgraded to Equal Weight from Overweight at Morgan Stanley
- 10/14/21 Cowen
- Exagen coverage transferred at Cowen
- 08/10/21 BTIG
- Exagen price target lowered to $20 from $23 at BTIG
- 04/15/21
- Fly Intel: Top five analyst initiations
- 04/15/21 Canaccord
- Canaccord starts Exagen at Buy, sees 50% upside potential
- 03/22/22
- Exagen sees FY22 revenue $51M-$53M, consensus $56.16M
- 03/22/22
- Exagen reports Q4 EPS (42c), consensus (50c)
- 11/10/21
- Exagen reports Q3 EPS (42c), consensus (46c)
- 02/17/22
- West Pharmaceutical sees FY22 EPS $9.20-$9.35, consensus $9.06
- 02/17/22
- West Pharmaceutical reports Q4 adjusted EPS $2.04, consensus $1.91
- 10/28/21
- West Pharmaceutical ups FY21 adjusted EPS view to $8.40-$8.50 from $8.05-$8.20
- 10/28/21
- West Pharmaceutical reports Q3 adjusted EPS $2.06, consensus $1.80
- 02/24/22
- Teleflex sees FY22 adjusted EPS $13.70-$14.30, consensus $14.04
- 02/24/22
- Teleflex reports Q4 adjusted EPS $3.60, consensus $3.53
- 10/28/21
- Teleflex raises 2021 adjusted EPS view to $13.15-$13.35 from $12.90-$13.10
- 10/28/21
- Teleflex reports Q3 adjusted EPS $3.51, consensus $3.03
- 02/01/22
- Premier lowers FY22 adjusted EPS view to $2.45-$2.55 from $2.56-$2.66
- 02/01/22
- Premier reports Q2 adjusted EPS 73c, consensus 65c
- 11/02/21
- Premier raises FY22 adjusted EPS view to $2.56-$2.66 from $2.50-$2.60
- 11/02/21
- Premier reports Q1 adjusted EPS 64c, consensus 59c
- 01/25/22
- NextGen Healthcare raises FY22 EPS view to 96c-$1.00 from 90c-96c
- 01/25/22
- NextGen Healthcare reports Q3 adjusted EPS 24c, consensus 21c
- 10/28/21
- NextGen Healthcare raises FY22 EPS view to 90c-96c from 89c-95c
- 10/28/21
- NextGen Healthcare reports Q2 EPS 29c, consensus 23c
MRVI Maravai Lifesciences - 02/23/22
- Maravai Lifesciences sees FY22 revenue $920M-$960M, consensus $863.92M
- 02/23/22
- Maravai Lifesciences reports Q4 EPS 42c, consensus 38c
- 11/11/21
- Maravai Lifesciences sees FY22 revenue $840M-$888M, consensus $789.84M
- 11/11/21
- Maravai Lifesciences sees FY21 adjusted EPS $1.48-$1.52, consensus $1.39
- 02/24/22
- LeMaitre reports Q4 EPS 28c, consensus 31c
- 10/28/21
- LeMaitre sees FY21 EPS $1.26-$1.31, consensus $1.35
- 10/28/21
- LeMaitre sees Q4 EPS 29c-34c, consensus 34c
- 10/28/21
- LeMaitre reports Q3 EPS 30c, consensus 32c
- 03/08/22
- Invacare sees Q1 revenue 'sequentially lower'
- 03/08/22
- Invacare reports Q4 EPS 8c, consensus 2c
- 10/27/21
- Invacare backs FY21 constant currency net sales growth view (1%)-2%
- 10/27/21
- Invacare reports Q3 adjusted EPS (12c), consensus (19c)
- 02/24/22
- Inogen reports Q4 EPS ($1.01), consensus (73c)
- 01/10/22
- Inogen reports preliminary Q4 revenue $75.9M-$76.9M, consensus $74.6M
- 11/04/21
- Inogen reports Q3 EPS 53c, consensus (26c)
- 02/24/22
- ICU Medical sees FY22 adjusted EPS $9.00-$10.50, consensus $7.76
- 02/24/22
- ICU Medical reports Q4 EPS 91c, consensus $1.64
- 11/03/21
- ICU Medical reports Q3 EPS $2.07, consensus $1.80
- 02/23/22
- Evolent Health sees 2022 revenue $1.12B-$1.18B, consensus $1.04B
- 02/23/22
- Evolent Health sees Q1 revenue$280M-$295M, consensus $250.06M
- 02/23/22
- Evolent Health reports Q4 adjusted EPS 8c, consensus 1c
- 11/03/21
- Evolent Health sees Q4 revenue $225M-$240M, consensus $227.18M
- 10/12/21
- Enzo Biochem reports Q4 EPS 7c vs. (7c) last year
EBS Emergent BioSolutions - 01/09/22
- Emergent BioSolutions sees preliminary FY21 revenue $1.78B, consensus $1.7B
- 11/04/21
- Emergent BioSolutions updates FY21 revenue view $1.7B-$1.8B from $1.7B-$1.9B
- 11/04/21
- Emergent BioSolutions reports Q3 adjusted EPS (36c), consensus $2.35
- 02/28/22
- Castle Biosciences sees FY22 revenue $115M-$120M, consensus $113.54M
- 02/28/22
- Castle Biosciences reports Q4 EPS (25c), consensus (47c)
- 11/08/21
- Castle Biosciences says on track to achieve FY21 revenue of $89M-$93M
- 11/08/21
- Castle Biosciences reports Q3 EPS (47c), consensus (40c)
- 02/28/22
- BioLife Solutions sees FY22 revenue $159.5M-$171.0M, consensus $159.1M
- 02/28/22
- BioLife Solutions reports Q4 EPS (22c), consensus (17c)
- 01/10/22
- BioLife Solutions sees FY21 revenue $119.12M, consensus $116.97M
- 01/10/22
- BioLife Solutions sees Q4 revenue $37.26M, consensus $35.12M
- 02/08/22
- Azenta sees Q2 non-GAAP EPS 7c-15c, consensus 11c
- 02/08/22
- Azenta reports Q1 non-GAAP EPS 12c, consensus 8c
- 02/03/22
- Avantor reports Q4 adjusted EPS 36c, consensus 33c
- 10/28/21
- Avantor reports Q3 adjusted EPS 35c, consensus 32c
- 10/12/21
- Avantor reports preliminary Q3 revenue $1.83B, consensus $1.82B
- 02/23/22
- Avanos sees 2022 adjusted EPS $1.55-$1.75, consensus $1.52
- 02/23/22
- Avanos reports Q4 adjusted EPS 46c, consensus 40c
- 11/02/21
- Avanos reports Q3 adjusted EPS 25c, consensus 30c
- 01/06/22
- AngioDynamics cuts FY22 adjusted EPS view to (2c)-2c from 0c-5c, consensus 2c
- 01/06/22
- AngioDynamics reports Q2 adjusted EPS (2c), consensus 0c
- 09/30/21
- AngioDynamics sees FY22 EPS 0c-5c, consensus 1c
- 09/30/21
- AngioDynamics reports Q1 EPS (2c), consensus (4c)
- 02/24/22
- Amwell sees FY22 revenue $275M-$285M, consensus $312.2M
- 02/24/22
- Amwell reports Q4 EPS (18c), consensus (27c)
- 11/10/21
- Amwell cuts FY21 revenue guidance to $246M-$253M from $252M-$262M
- 11/10/21
- Amwell reports Q3 EPS (20c), consensus (24c)
- 03/08/22
- Agiliti sees FY22 adjusted EPS 89c-94c, consensus 73c
- 03/08/22
- Agiliti reports Q4 adjusted EPS 25c, consensus 9c
- 11/09/21
- Agiliti raises FY21 revenue view to $1.01B-$1.02B from $965M-$980M
- 11/09/21
- Agiliti reports Q3 adjusted EPS 23c, consensus 9c
|
Conference/Events
|
Life Sciences &… Life Sciences & MedTech Virtual Forum to be held on March 22-23. ShowHide Related Items >><< - 10/27/21
- Exagen expands coverage with Inland Empire Health Plan
- 10/25/21
- Exagen announces $27.2M debt refinancing
- 02/28/22
- West Pharmaceutical names Eric Green as Chair of Board
- 01/25/22
- West Pharmaceutical enters supply, technology agreement with Corning
- 02/23/22
- Teleflex: FDA clears expanded indication for specialty catheters
- 03/14/22
- Sodexo announces national GPO agreement with Premier
- 10/26/21
- Premier, Resilinc announce supply chain transparency collaboration
- 12/15/21
- NextGen Healthcare CMO Betty Rabinowitz to retire, Robert Murry to succeed
- 10/28/21
- NextGen Healthcare announces $60M share repurchase program
- 10/05/21
- Proxy firms ISS and Glass Lewis support NextGen Healthcare director nominees
- 09/28/21
- NextGen Healthcare provides presentation amid proxy fight against Sheldon Razin
MRVI Maravai Lifesciences - 02/25/22
- Maravai Lifesciences up 10% after Reuters says rejected $42 per share bid
- 01/28/22
- Maravai Lifesciences acquires MyChem for $240M in cash
- 12/14/21
- Maravai Lifesciences added to the Nasdaq Biotechnology Index
- 11/29/21
- Codex DNA announces commercial availability of BioXp mRNA synthesis kits
- 02/24/22
- LeMaitre announces $20M share repurchase authorization
- 03/08/22
- Invacare sees FY22 adjusted EBITDA, free cash fow up from FY21
- 12/01/21
- Invacare realigns EMEA, Asia Pacific businesses
- 11/30/21
- FDA posts warning letter sent to Invacare on November 18
- 11/05/21
- NetScout to replace Invacare in S&P 600 at open on 11/5
- 03/04/22
- Inogen names Kristin Caltrider as CFO, succeeding Mike Sergesketter
- 02/24/22
- Inogen sees Q1 revenue similar to Q4, sees FY22 revenue up mid-single digits
- 12/30/21
- Inogen appoints Elizabeth Mora as board chairperson
- 12/13/21
- Inogen announces Sergesketter as Interim Chief Financial Officer
- 03/07/22
- Evolent Health expects to continue provision of services to Cook County Health
- 02/24/22
- Evolent Health rises 16.3%
- 10/15/21
- Evolent Health up 2% as Dealreporter speculates on deal fit with Walgreens
- 09/29/21
- Evolent Health trading resumes
- 01/03/22
- Enzo Biochem appoints CEO Hamid Erfanian to board
- 10/25/21
- Radoff issues letter to Enzo independent directors regarding shareholder unrest
- 10/21/21
- Enzo Biochem expands GoTestMeNow online portal
- 10/18/21
- Enzo Biochem appoints Hamid Erfanian as Chief Executive Officer
EBS Emergent BioSolutions - 03/11/22
- Emergent BioSolutions initiates Phase 1 study of SIAN
- 02/18/22
- FDA says added four lots of AstraZeneca COVID vaccine acceptable for export
- 02/11/22
- Emergent BioSolutions 'disappointed' in appeals ruling in Narcan case with Teva
- 01/14/22
- Emergent BioSolutions founder and executive chairman, Fuad El-Hibri, to retire
- 01/12/22
- Castle Biosciences publishes sequencing panel study for melanoma analysis
- 11/24/21
- Castle presents data backing clinical utility of DecisionDx portfolio
- 11/19/21
- Castle Biosciences announces publication of DecisionDx-Melanoma data
- 10/25/21
- Castle Biosciences acquiring Pittsburgh Life Science Greenhouse's Cernostics
- 03/18/22
- BioLife Solutions receives Nasdaq notice of noncompliance for delayed 10-K
- 03/17/22
- BioLife Solutions announces additional delay in filing Form 10-K
- 11/04/21
- BioLife Solutions names Troy Wichterman as CFO, Roderick de Greef as COO
- 01/06/22
- Azenta names Matthew McManus as COO
- 11/16/21
- Brooks Automation to change name to Azenta, effective December 1
- 02/15/22
- Avantor chairman Rajiv Gupta to retire
- 02/11/22
- Avantor starts construction on new distribution center in Ireland
- 11/15/21
- Third Point buys Alight, exits Uber in Q3
- 09/22/21
- Avantor CEO sells 141.3K shares of common stock
- 12/15/21
- Avanos announces $30M share repurchase program
- 12/13/21
- Avanos to acquire OrthogenRx, Inc. for $160M
- 01/12/22
- AngioDynamics CEO buys $228K in common stock
- 03/09/22 Citi
- Agiliti price target lowered to $25 from $28 at Citi
- 01/10/22 Citi
- Agiliti assumed with a Buy at Citi
- 08/16/21 Citi
- Citi says Agiliti selloff overdone, boosts target to $22
- 05/26/21 BMO Capital
- Agiliti price target raised to $26 from $18 at BMO Capital
- 02/25/22 Piper Sandler
- Amwell price target lowered to $7 from $12 at Piper Sandler
- 02/11/22 Goldman Sachs
- Amwell initiated with a Neutral at Goldman Sachs
- 12/01/21 Jefferies
- Amwell initiated with a Hold at Jefferies
- 11/22/21 Piper Sandler
- Piper remains buyer of Amwell despite chat supporting below consensus FY22 view
- 01/07/22 Canaccord
- AngioDynamics price target lowered to $34 from $37 at Canaccord
- 10/15/21
- Fly Intel: Top five analyst upgrades
- 10/15/21 Canaccord
- AngioDynamics upgraded to Buy at Canaccord on future growth clarity
- 10/15/21 Canaccord
- AngioDynamics upgraded to Buy from Hold at Canaccord
- 02/24/22 KeyBanc
- Avanos price target lowered to $41 from $47 at KeyBanc
- 08/04/21 KeyBanc
- Avanos price target lowered to $47 from $55 at KeyBanc
- 08/04/21 Stephens
- Avanos downgraded to Equal Weight from Overweight at Stephens
- 02/07/22 Raymond James
- Avantor price target lowered to $43 from $47 at Raymond James
- 02/07/22 Baird
- Avantor price target lowered to $43 from $44 at Baird
- 02/07/22 Barclays
- Avantor price target raised to $44 from $41 at Barclays
- 01/27/22 Barclays
- Avantor price target lowered to $41 from $48 at Barclays
- 03/21/22 Evercore ISI
- Azenta initiated with an Outperform at Evercore ISI
- 02/09/22 Needham
- Azenta price target lowered to $115 from $155 at Needham
- 11/17/21 Stifel
- Brooks Automation price target raised to $149 from $134 at Stifel
- 11/17/21 Stephens
- Brooks Automation price target raised to $137 from $130 at Stephens
- 03/02/22 B. Riley
- BioLife Solutions price target lowered to $48 from $67 at B. Riley
- 01/03/22 Stephens
- Wendy's, Kirby and Vizio among Stephens' 2022 Best Ideas
- 12/31/21 Northland
- BioLife Solutions named a top pick for 2022 at Northland
- 10/19/21 B. Riley
- BioLife Solutions transferred with Buy, $61 target at B. Riley
- 03/01/22 Lake Street
- Castle Biosciences price target lowered to $63 from $94 at Lake Street
- 03/01/22 Baird
- Castle Biosciences price target lowered to $60 from $82 at Baird
- 01/06/22 Stephens
- Stephens starts skin cancer test leader Castle Biosciences at Overweight
- 01/06/22 Stephens
- Castle Biosciences initiated with an Overweight at Stephens
EBS Emergent BioSolutions - 01/20/22 Cantor Fitzgerald
- Emergent BioSolutions price target raised to $55 from $50 at Cantor Fitzgerald
- 01/20/22 Benchmark
- Emergent BioSolutions upgraded to Buy from Hold at Benchmark
- 12/27/21 Cowen
- Emergent's Narcan sales under immediate threat, says Cowen
- 11/10/21 Chardan
- Emergent BioSolutions price target lowered to $75 from $92 at Chardan
- 03/08/22 Cowen
- Evolent Health remains top pick after meeting with management, says Cowen
- 03/07/22 Piper Sandler
- Evolent Health news removes $82M overhang, says Piper Sandler
- 03/04/22 Piper Sandler
- Bright Health expansion big revenue opportunity for Evolent, says Piper
- 02/24/22 Piper Sandler
- Evolent Health price target lowered to $32 from $36 at Piper Sandler
- 09/09/21 Raymond James
- ICU Medical price target raised to $286 from $220 at Raymond James
- 12/09/21 Needham
- Inogen upgraded to Buy from Hold at Needham
- 12/09/21 Needham
- Inogen upgraded to Buy from Hold at Needham
- 11/02/21
- Fly Intel: Top five analyst upgrades
- 11/02/21 JPMorgan
- Inogen upgraded to Neutral with risks priced in at JPMorgan
- 09/10/21 Needham
- Invacare price target lowered to $8 from $17 at Needham
- 08/19/21 Oppenheimer
- Invacare initiated with an Outperform at Oppenheimer
- 02/25/22 Barrington
- LeMaitre price target lowered to $54 from $62 at Barrington
- 09/16/21
- Fly Intel: Top five analyst initiations
- 09/16/21 Jefferies
- Jefferies starts LeMaitre at Buy on ArteGraft upside potential
- 09/16/21 Jefferies
- LeMaitre initiated with a Buy at Jefferies
MRVI Maravai Lifesciences - 02/28/22 William Blair
- Maravai buyout price would need to be well into $50s, says William Blair
- 02/24/22 Baird
- Maravai Lifesciences price target lowered to $48 from $60 at Baird
- 10/01/21 Morgan Stanley
- Maravai selloff on Merck's molnupiravir data overdone, says Morgan Stanley
- 08/11/21 Credit Suisse
- Maravai Lifesciences price target raised to $54 from $44 at Credit Suisse
- 01/26/22 Piper Sandler
- NextGen Healthcare price target raised to $24 from $23 at Piper Sandler
- 01/06/22 SVB Leerink
- SVB Leerink upgrades NextGen Healthcare to Outperform with $22 price target
- 01/06/22 SVB Leerink
- NextGen Healthcare upgraded to Outperform from Market Perform at SVB Leerink
- 01/05/22 Piper Sandler
- NextGen Healthcare named a 2022 top pick at Piper Sandler
- 11/18/21 Barclays
- Premier price target raised to $36 from $34 at Barclays
- 11/03/21 Piper Sandler
- Premier price target raised to $39 from $31 at Piper Sandler
- 05/28/21
- Fly Intel: Top five analyst downgrades
- 05/28/21 Barclays
- Barclays double downgrades Premier with multiple expansion less likely
- 02/24/22 Piper Sandler
- Teleflex price target raised to $335 from $320 at Piper Sandler
- 01/21/22 Piper Sandler
- Teleflex price target lowered to $320 from $325 at Piper Sandler
- 01/07/22 Morgan Stanley
- Teleflex cut to Equal Weight at Morgan Stanley on near-term UroLift caution
- 01/07/22 Morgan Stanley
- Teleflex downgraded to Equal Weight from Overweight at Morgan Stanley
- 10/14/21 Cowen
- Exagen coverage transferred at Cowen
- 08/10/21 BTIG
- Exagen price target lowered to $20 from $23 at BTIG
- 04/15/21
- Fly Intel: Top five analyst initiations
- 04/15/21 Canaccord
- Canaccord starts Exagen at Buy, sees 50% upside potential
- 11/10/21
- Exagen reports Q3 EPS (42c), consensus (46c)
- 02/17/22
- West Pharmaceutical sees FY22 EPS $9.20-$9.35, consensus $9.06
- 02/17/22
- West Pharmaceutical reports Q4 adjusted EPS $2.04, consensus $1.91
- 10/28/21
- West Pharmaceutical ups FY21 adjusted EPS view to $8.40-$8.50 from $8.05-$8.20
- 10/28/21
- West Pharmaceutical reports Q3 adjusted EPS $2.06, consensus $1.80
- 02/24/22
- Teleflex sees FY22 adjusted EPS $13.70-$14.30, consensus $14.04
- 02/24/22
- Teleflex reports Q4 adjusted EPS $3.60, consensus $3.53
- 10/28/21
- Teleflex raises 2021 adjusted EPS view to $13.15-$13.35 from $12.90-$13.10
- 10/28/21
- Teleflex reports Q3 adjusted EPS $3.51, consensus $3.03
- 02/01/22
- Premier lowers FY22 adjusted EPS view to $2.45-$2.55 from $2.56-$2.66
- 02/01/22
- Premier reports Q2 adjusted EPS 73c, consensus 65c
- 11/02/21
- Premier raises FY22 adjusted EPS view to $2.56-$2.66 from $2.50-$2.60
- 11/02/21
- Premier reports Q1 adjusted EPS 64c, consensus 59c
- 01/25/22
- NextGen Healthcare raises FY22 EPS view to 96c-$1.00 from 90c-96c
- 01/25/22
- NextGen Healthcare reports Q3 adjusted EPS 24c, consensus 21c
- 10/28/21
- NextGen Healthcare raises FY22 EPS view to 90c-96c from 89c-95c
- 10/28/21
- NextGen Healthcare reports Q2 EPS 29c, consensus 23c
MRVI Maravai Lifesciences - 02/23/22
- Maravai Lifesciences sees FY22 revenue $920M-$960M, consensus $863.92M
- 02/23/22
- Maravai Lifesciences reports Q4 EPS 42c, consensus 38c
- 11/11/21
- Maravai Lifesciences sees FY22 revenue $840M-$888M, consensus $789.84M
- 11/11/21
- Maravai Lifesciences sees FY21 adjusted EPS $1.48-$1.52, consensus $1.39
- 02/24/22
- LeMaitre reports Q4 EPS 28c, consensus 31c
- 10/28/21
- LeMaitre sees FY21 EPS $1.26-$1.31, consensus $1.35
- 10/28/21
- LeMaitre sees Q4 EPS 29c-34c, consensus 34c
- 10/28/21
- LeMaitre reports Q3 EPS 30c, consensus 32c
- 03/08/22
- Invacare sees Q1 revenue 'sequentially lower'
- 03/08/22
- Invacare reports Q4 EPS 8c, consensus 2c
- 10/27/21
- Invacare backs FY21 constant currency net sales growth view (1%)-2%
- 10/27/21
- Invacare reports Q3 adjusted EPS (12c), consensus (19c)
- 02/24/22
- Inogen reports Q4 EPS ($1.01), consensus (73c)
- 01/10/22
- Inogen reports preliminary Q4 revenue $75.9M-$76.9M, consensus $74.6M
- 11/04/21
- Inogen reports Q3 EPS 53c, consensus (26c)
- 02/24/22
- ICU Medical sees FY22 adjusted EPS $9.00-$10.50, consensus $7.76
- 02/24/22
- ICU Medical reports Q4 EPS 91c, consensus $1.64
- 11/03/21
- ICU Medical reports Q3 EPS $2.07, consensus $1.80
- 02/23/22
- Evolent Health sees 2022 revenue $1.12B-$1.18B, consensus $1.04B
- 02/23/22
- Evolent Health sees Q1 revenue$280M-$295M, consensus $250.06M
- 02/23/22
- Evolent Health reports Q4 adjusted EPS 8c, consensus 1c
- 11/03/21
- Evolent Health sees Q4 revenue $225M-$240M, consensus $227.18M
- 10/12/21
- Enzo Biochem reports Q4 EPS 7c vs. (7c) last year
EBS Emergent BioSolutions - 01/09/22
- Emergent BioSolutions sees preliminary FY21 revenue $1.78B, consensus $1.7B
- 11/04/21
- Emergent BioSolutions updates FY21 revenue view $1.7B-$1.8B from $1.7B-$1.9B
- 11/04/21
- Emergent BioSolutions reports Q3 adjusted EPS (36c), consensus $2.35
- 02/28/22
- Castle Biosciences sees FY22 revenue $115M-$120M, consensus $113.54M
- 02/28/22
- Castle Biosciences reports Q4 EPS (25c), consensus (47c)
- 11/08/21
- Castle Biosciences says on track to achieve FY21 revenue of $89M-$93M
- 11/08/21
- Castle Biosciences reports Q3 EPS (47c), consensus (40c)
- 02/28/22
- BioLife Solutions sees FY22 revenue $159.5M-$171.0M, consensus $159.1M
- 02/28/22
- BioLife Solutions reports Q4 EPS (22c), consensus (17c)
- 01/10/22
- BioLife Solutions sees FY21 revenue $119.12M, consensus $116.97M
- 01/10/22
- BioLife Solutions sees Q4 revenue $37.26M, consensus $35.12M
- 02/08/22
- Azenta sees Q2 non-GAAP EPS 7c-15c, consensus 11c
- 02/08/22
- Azenta reports Q1 non-GAAP EPS 12c, consensus 8c
- 02/03/22
- Avantor reports Q4 adjusted EPS 36c, consensus 33c
- 10/28/21
- Avantor reports Q3 adjusted EPS 35c, consensus 32c
- 10/12/21
- Avantor reports preliminary Q3 revenue $1.83B, consensus $1.82B
- 02/23/22
- Avanos sees 2022 adjusted EPS $1.55-$1.75, consensus $1.52
- 02/23/22
- Avanos reports Q4 adjusted EPS 46c, consensus 40c
- 11/02/21
- Avanos reports Q3 adjusted EPS 25c, consensus 30c
- 01/06/22
- AngioDynamics cuts FY22 adjusted EPS view to (2c)-2c from 0c-5c, consensus 2c
- 01/06/22
- AngioDynamics reports Q2 adjusted EPS (2c), consensus 0c
- 09/30/21
- AngioDynamics sees FY22 EPS 0c-5c, consensus 1c
- 09/30/21
- AngioDynamics reports Q1 EPS (2c), consensus (4c)
- 02/24/22
- Amwell sees FY22 revenue $275M-$285M, consensus $312.2M
- 02/24/22
- Amwell reports Q4 EPS (18c), consensus (27c)
- 11/10/21
- Amwell cuts FY21 revenue guidance to $246M-$253M from $252M-$262M
- 11/10/21
- Amwell reports Q3 EPS (20c), consensus (24c)
- 03/08/22
- Agiliti sees FY22 adjusted EPS 89c-94c, consensus 73c
- 03/08/22
- Agiliti reports Q4 adjusted EPS 25c, consensus 9c
- 11/09/21
- Agiliti raises FY21 revenue view to $1.01B-$1.02B from $965M-$980M
- 11/09/21
- Agiliti reports Q3 adjusted EPS 23c, consensus 9c
|
Conference/Events
|
Life Sciences &… Life Sciences & MedTech Virtual Forum to be held on March 22-23. ShowHide Related Items >><< - 10/27/21
- Exagen expands coverage with Inland Empire Health Plan
- 10/25/21
- Exagen announces $27.2M debt refinancing
- 02/28/22
- West Pharmaceutical names Eric Green as Chair of Board
- 01/25/22
- West Pharmaceutical enters supply, technology agreement with Corning
- 02/23/22
- Teleflex: FDA clears expanded indication for specialty catheters
- 03/14/22
- Sodexo announces national GPO agreement with Premier
- 10/26/21
- Premier, Resilinc announce supply chain transparency collaboration
- 12/15/21
- NextGen Healthcare CMO Betty Rabinowitz to retire, Robert Murry to succeed
- 10/28/21
- NextGen Healthcare announces $60M share repurchase program
- 10/05/21
- Proxy firms ISS and Glass Lewis support NextGen Healthcare director nominees
- 09/28/21
- NextGen Healthcare provides presentation amid proxy fight against Sheldon Razin
MRVI Maravai Lifesciences - 02/25/22
- Maravai Lifesciences up 10% after Reuters says rejected $42 per share bid
- 01/28/22
- Maravai Lifesciences acquires MyChem for $240M in cash
- 12/14/21
- Maravai Lifesciences added to the Nasdaq Biotechnology Index
- 11/29/21
- Codex DNA announces commercial availability of BioXp mRNA synthesis kits
- 02/24/22
- LeMaitre announces $20M share repurchase authorization
- 03/08/22
- Invacare sees FY22 adjusted EBITDA, free cash fow up from FY21
- 12/01/21
- Invacare realigns EMEA, Asia Pacific businesses
- 11/30/21
- FDA posts warning letter sent to Invacare on November 18
- 11/05/21
- NetScout to replace Invacare in S&P 600 at open on 11/5
- 03/04/22
- Inogen names Kristin Caltrider as CFO, succeeding Mike Sergesketter
- 02/24/22
- Inogen sees Q1 revenue similar to Q4, sees FY22 revenue up mid-single digits
- 12/30/21
- Inogen appoints Elizabeth Mora as board chairperson
- 12/13/21
- Inogen announces Sergesketter as Interim Chief Financial Officer
- 03/07/22
- Evolent Health expects to continue provision of services to Cook County Health
- 02/24/22
- Evolent Health rises 16.3%
- 10/15/21
- Evolent Health up 2% as Dealreporter speculates on deal fit with Walgreens
- 09/29/21
- Evolent Health trading resumes
- 01/03/22
- Enzo Biochem appoints CEO Hamid Erfanian to board
- 10/25/21
- Radoff issues letter to Enzo independent directors regarding shareholder unrest
- 10/21/21
- Enzo Biochem expands GoTestMeNow online portal
- 10/18/21
- Enzo Biochem appoints Hamid Erfanian as Chief Executive Officer
EBS Emergent BioSolutions - 03/11/22
- Emergent BioSolutions initiates Phase 1 study of SIAN
- 02/18/22
- FDA says added four lots of AstraZeneca COVID vaccine acceptable for export
- 02/11/22
- Emergent BioSolutions 'disappointed' in appeals ruling in Narcan case with Teva
- 01/14/22
- Emergent BioSolutions founder and executive chairman, Fuad El-Hibri, to retire
- 01/12/22
- Castle Biosciences publishes sequencing panel study for melanoma analysis
- 11/24/21
- Castle presents data backing clinical utility of DecisionDx portfolio
- 11/19/21
- Castle Biosciences announces publication of DecisionDx-Melanoma data
- 10/25/21
- Castle Biosciences acquiring Pittsburgh Life Science Greenhouse's Cernostics
- 03/18/22
- BioLife Solutions receives Nasdaq notice of noncompliance for delayed 10-K
- 03/17/22
- BioLife Solutions announces additional delay in filing Form 10-K
- 11/04/21
- BioLife Solutions names Troy Wichterman as CFO, Roderick de Greef as COO
- 01/06/22
- Azenta names Matthew McManus as COO
- 11/16/21
- Brooks Automation to change name to Azenta, effective December 1
- 02/15/22
- Avantor chairman Rajiv Gupta to retire
- 02/11/22
- Avantor starts construction on new distribution center in Ireland
- 11/15/21
- Third Point buys Alight, exits Uber in Q3
- 09/22/21
- Avantor CEO sells 141.3K shares of common stock
- 12/15/21
- Avanos announces $30M share repurchase program
- 12/13/21
- Avanos to acquire OrthogenRx, Inc. for $160M
- 01/12/22
- AngioDynamics CEO buys $228K in common stock
- 09/21/21
- Amwell appoints Robert Shepardson as CFO
- 03/09/22 Citi
- Agiliti price target lowered to $25 from $28 at Citi
- 01/10/22 Citi
- Agiliti assumed with a Buy at Citi
- 08/16/21 Citi
- Citi says Agiliti selloff overdone, boosts target to $22
- 05/26/21 BMO Capital
- Agiliti price target raised to $26 from $18 at BMO Capital
- 02/25/22 Piper Sandler
- Amwell price target lowered to $7 from $12 at Piper Sandler
- 02/11/22 Goldman Sachs
- Amwell initiated with a Neutral at Goldman Sachs
- 12/01/21 Jefferies
- Amwell initiated with a Hold at Jefferies
- 11/22/21 Piper Sandler
- Piper remains buyer of Amwell despite chat supporting below consensus FY22 view
- 01/07/22 Canaccord
- AngioDynamics price target lowered to $34 from $37 at Canaccord
- 10/15/21
- Fly Intel: Top five analyst upgrades
- 10/15/21 Canaccord
- AngioDynamics upgraded to Buy at Canaccord on future growth clarity
- 10/15/21 Canaccord
- AngioDynamics upgraded to Buy from Hold at Canaccord
- 02/24/22 KeyBanc
- Avanos price target lowered to $41 from $47 at KeyBanc
- 08/04/21 KeyBanc
- Avanos price target lowered to $47 from $55 at KeyBanc
- 08/04/21 Stephens
- Avanos downgraded to Equal Weight from Overweight at Stephens
- 02/07/22 Raymond James
- Avantor price target lowered to $43 from $47 at Raymond James
- 02/07/22 Baird
- Avantor price target lowered to $43 from $44 at Baird
- 02/07/22 Barclays
- Avantor price target raised to $44 from $41 at Barclays
- 01/27/22 Barclays
- Avantor price target lowered to $41 from $48 at Barclays
- 03/21/22 Evercore ISI
- Azenta initiated with an Outperform at Evercore ISI
- 02/09/22 Needham
- Azenta price target lowered to $115 from $155 at Needham
- 11/17/21 Stifel
- Brooks Automation price target raised to $149 from $134 at Stifel
- 11/17/21 Stephens
- Brooks Automation price target raised to $137 from $130 at Stephens
- 03/02/22 B. Riley
- BioLife Solutions price target lowered to $48 from $67 at B. Riley
- 01/03/22 Stephens
- Wendy's, Kirby and Vizio among Stephens' 2022 Best Ideas
- 12/31/21 Northland
- BioLife Solutions named a top pick for 2022 at Northland
- 10/19/21 B. Riley
- BioLife Solutions transferred with Buy, $61 target at B. Riley
- 03/01/22 Lake Street
- Castle Biosciences price target lowered to $63 from $94 at Lake Street
- 03/01/22 Baird
- Castle Biosciences price target lowered to $60 from $82 at Baird
- 01/06/22 Stephens
- Stephens starts skin cancer test leader Castle Biosciences at Overweight
- 01/06/22 Stephens
- Castle Biosciences initiated with an Overweight at Stephens
EBS Emergent BioSolutions - 01/20/22 Cantor Fitzgerald
- Emergent BioSolutions price target raised to $55 from $50 at Cantor Fitzgerald
- 01/20/22 Benchmark
- Emergent BioSolutions upgraded to Buy from Hold at Benchmark
- 12/27/21 Cowen
- Emergent's Narcan sales under immediate threat, says Cowen
- 11/10/21 Chardan
- Emergent BioSolutions price target lowered to $75 from $92 at Chardan
- 03/08/22 Cowen
- Evolent Health remains top pick after meeting with management, says Cowen
- 03/07/22 Piper Sandler
- Evolent Health news removes $82M overhang, says Piper Sandler
- 03/04/22 Piper Sandler
- Bright Health expansion big revenue opportunity for Evolent, says Piper
- 02/24/22 Piper Sandler
- Evolent Health price target lowered to $32 from $36 at Piper Sandler
- 09/09/21 Raymond James
- ICU Medical price target raised to $286 from $220 at Raymond James
- 12/09/21 Needham
- Inogen upgraded to Buy from Hold at Needham
- 12/09/21 Needham
- Inogen upgraded to Buy from Hold at Needham
- 11/02/21
- Fly Intel: Top five analyst upgrades
- 11/02/21 JPMorgan
- Inogen upgraded to Neutral with risks priced in at JPMorgan
- 09/10/21 Needham
- Invacare price target lowered to $8 from $17 at Needham
- 08/19/21 Oppenheimer
- Invacare initiated with an Outperform at Oppenheimer
- 02/25/22 Barrington
- LeMaitre price target lowered to $54 from $62 at Barrington
- 09/16/21
- Fly Intel: Top five analyst initiations
- 09/16/21 Jefferies
- Jefferies starts LeMaitre at Buy on ArteGraft upside potential
- 09/16/21 Jefferies
- LeMaitre initiated with a Buy at Jefferies
MRVI Maravai Lifesciences - 02/28/22 William Blair
- Maravai buyout price would need to be well into $50s, says William Blair
- 02/24/22 Baird
- Maravai Lifesciences price target lowered to $48 from $60 at Baird
- 10/01/21 Morgan Stanley
- Maravai selloff on Merck's molnupiravir data overdone, says Morgan Stanley
- 08/11/21 Credit Suisse
- Maravai Lifesciences price target raised to $54 from $44 at Credit Suisse
- 01/26/22 Piper Sandler
- NextGen Healthcare price target raised to $24 from $23 at Piper Sandler
- 01/06/22 SVB Leerink
- SVB Leerink upgrades NextGen Healthcare to Outperform with $22 price target
- 01/06/22 SVB Leerink
- NextGen Healthcare upgraded to Outperform from Market Perform at SVB Leerink
- 01/05/22 Piper Sandler
- NextGen Healthcare named a 2022 top pick at Piper Sandler
- 11/18/21 Barclays
- Premier price target raised to $36 from $34 at Barclays
- 11/03/21 Piper Sandler
- Premier price target raised to $39 from $31 at Piper Sandler
- 05/28/21
- Fly Intel: Top five analyst downgrades
- 05/28/21 Barclays
- Barclays double downgrades Premier with multiple expansion less likely
- 02/24/22 Piper Sandler
- Teleflex price target raised to $335 from $320 at Piper Sandler
- 01/21/22 Piper Sandler
- Teleflex price target lowered to $320 from $325 at Piper Sandler
- 01/07/22 Morgan Stanley
- Teleflex cut to Equal Weight at Morgan Stanley on near-term UroLift caution
- 01/07/22 Morgan Stanley
- Teleflex downgraded to Equal Weight from Overweight at Morgan Stanley
- 10/14/21 Cowen
- Exagen coverage transferred at Cowen
- 08/10/21 BTIG
- Exagen price target lowered to $20 from $23 at BTIG
- 04/15/21
- Fly Intel: Top five analyst initiations
- 04/15/21 Canaccord
- Canaccord starts Exagen at Buy, sees 50% upside potential
- 11/10/21
- Exagen reports Q3 EPS (42c), consensus (46c)
- 02/17/22
- West Pharmaceutical sees FY22 EPS $9.20-$9.35, consensus $9.06
- 02/17/22
- West Pharmaceutical reports Q4 adjusted EPS $2.04, consensus $1.91
- 10/28/21
- West Pharmaceutical ups FY21 adjusted EPS view to $8.40-$8.50 from $8.05-$8.20
- 10/28/21
- West Pharmaceutical reports Q3 adjusted EPS $2.06, consensus $1.80
- 02/24/22
- Teleflex sees FY22 adjusted EPS $13.70-$14.30, consensus $14.04
- 02/24/22
- Teleflex reports Q4 adjusted EPS $3.60, consensus $3.53
- 10/28/21
- Teleflex raises 2021 adjusted EPS view to $13.15-$13.35 from $12.90-$13.10
- 10/28/21
- Teleflex reports Q3 adjusted EPS $3.51, consensus $3.03
- 02/01/22
- Premier lowers FY22 adjusted EPS view to $2.45-$2.55 from $2.56-$2.66
- 02/01/22
- Premier reports Q2 adjusted EPS 73c, consensus 65c
- 11/02/21
- Premier raises FY22 adjusted EPS view to $2.56-$2.66 from $2.50-$2.60
- 11/02/21
- Premier reports Q1 adjusted EPS 64c, consensus 59c
- 01/25/22
- NextGen Healthcare raises FY22 EPS view to 96c-$1.00 from 90c-96c
- 01/25/22
- NextGen Healthcare reports Q3 adjusted EPS 24c, consensus 21c
- 10/28/21
- NextGen Healthcare raises FY22 EPS view to 90c-96c from 89c-95c
- 10/28/21
- NextGen Healthcare reports Q2 EPS 29c, consensus 23c
MRVI Maravai Lifesciences - 02/23/22
- Maravai Lifesciences sees FY22 revenue $920M-$960M, consensus $863.92M
- 02/23/22
- Maravai Lifesciences reports Q4 EPS 42c, consensus 38c
- 11/11/21
- Maravai Lifesciences sees FY22 revenue $840M-$888M, consensus $789.84M
- 11/11/21
- Maravai Lifesciences sees FY21 adjusted EPS $1.48-$1.52, consensus $1.39
- 02/24/22
- LeMaitre reports Q4 EPS 28c, consensus 31c
- 10/28/21
- LeMaitre sees FY21 EPS $1.26-$1.31, consensus $1.35
- 10/28/21
- LeMaitre sees Q4 EPS 29c-34c, consensus 34c
- 10/28/21
- LeMaitre reports Q3 EPS 30c, consensus 32c
- 03/08/22
- Invacare sees Q1 revenue 'sequentially lower'
- 03/08/22
- Invacare reports Q4 EPS 8c, consensus 2c
- 10/27/21
- Invacare backs FY21 constant currency net sales growth view (1%)-2%
- 10/27/21
- Invacare reports Q3 adjusted EPS (12c), consensus (19c)
- 02/24/22
- Inogen reports Q4 EPS ($1.01), consensus (73c)
- 01/10/22
- Inogen reports preliminary Q4 revenue $75.9M-$76.9M, consensus $74.6M
- 11/04/21
- Inogen reports Q3 EPS 53c, consensus (26c)
- 02/24/22
- ICU Medical sees FY22 adjusted EPS $9.00-$10.50, consensus $7.76
- 02/24/22
- ICU Medical reports Q4 EPS 91c, consensus $1.64
- 11/03/21
- ICU Medical reports Q3 EPS $2.07, consensus $1.80
- 02/23/22
- Evolent Health sees 2022 revenue $1.12B-$1.18B, consensus $1.04B
- 02/23/22
- Evolent Health sees Q1 revenue$280M-$295M, consensus $250.06M
- 02/23/22
- Evolent Health reports Q4 adjusted EPS 8c, consensus 1c
- 11/03/21
- Evolent Health sees Q4 revenue $225M-$240M, consensus $227.18M
- 10/12/21
- Enzo Biochem reports Q4 EPS 7c vs. (7c) last year
EBS Emergent BioSolutions - 01/09/22
- Emergent BioSolutions sees preliminary FY21 revenue $1.78B, consensus $1.7B
- 11/04/21
- Emergent BioSolutions updates FY21 revenue view $1.7B-$1.8B from $1.7B-$1.9B
- 11/04/21
- Emergent BioSolutions reports Q3 adjusted EPS (36c), consensus $2.35
- 02/28/22
- Castle Biosciences sees FY22 revenue $115M-$120M, consensus $113.54M
- 02/28/22
- Castle Biosciences reports Q4 EPS (25c), consensus (47c)
- 11/08/21
- Castle Biosciences says on track to achieve FY21 revenue of $89M-$93M
- 11/08/21
- Castle Biosciences reports Q3 EPS (47c), consensus (40c)
- 02/28/22
- BioLife Solutions sees FY22 revenue $159.5M-$171.0M, consensus $159.1M
- 02/28/22
- BioLife Solutions reports Q4 EPS (22c), consensus (17c)
- 01/10/22
- BioLife Solutions sees FY21 revenue $119.12M, consensus $116.97M
- 01/10/22
- BioLife Solutions sees Q4 revenue $37.26M, consensus $35.12M
- 02/08/22
- Azenta sees Q2 non-GAAP EPS 7c-15c, consensus 11c
- 02/08/22
- Azenta reports Q1 non-GAAP EPS 12c, consensus 8c
- 02/03/22
- Avantor reports Q4 adjusted EPS 36c, consensus 33c
- 10/28/21
- Avantor reports Q3 adjusted EPS 35c, consensus 32c
- 10/12/21
- Avantor reports preliminary Q3 revenue $1.83B, consensus $1.82B
- 02/23/22
- Avanos sees 2022 adjusted EPS $1.55-$1.75, consensus $1.52
- 02/23/22
- Avanos reports Q4 adjusted EPS 46c, consensus 40c
- 11/02/21
- Avanos reports Q3 adjusted EPS 25c, consensus 30c
- 01/06/22
- AngioDynamics cuts FY22 adjusted EPS view to (2c)-2c from 0c-5c, consensus 2c
- 01/06/22
- AngioDynamics reports Q2 adjusted EPS (2c), consensus 0c
- 09/30/21
- AngioDynamics sees FY22 EPS 0c-5c, consensus 1c
- 09/30/21
- AngioDynamics reports Q1 EPS (2c), consensus (4c)
- 02/24/22
- Amwell sees FY22 revenue $275M-$285M, consensus $312.2M
- 02/24/22
- Amwell reports Q4 EPS (18c), consensus (27c)
- 11/10/21
- Amwell cuts FY21 revenue guidance to $246M-$253M from $252M-$262M
- 11/10/21
- Amwell reports Q3 EPS (20c), consensus (24c)
- 03/08/22
- Agiliti sees FY22 adjusted EPS 89c-94c, consensus 73c
- 03/08/22
- Agiliti reports Q4 adjusted EPS 25c, consensus 9c
- 11/09/21
- Agiliti raises FY21 revenue view to $1.01B-$1.02B from $965M-$980M
- 11/09/21
- Agiliti reports Q3 adjusted EPS 23c, consensus 9c
|
On The Fly
| ShowHide Related Items >><< - 03/14/22
- Urban-Gro to acquire Emerald Construction Management for $7M
- 02/02/22
- Urban-Gro announces additional $1.5M expansion of stock repurchase program
- 01/18/22
- Urban-Gro board approves $2M increase to existing stock repurchase program
- 01/06/22
- Urban-Gro named as authorized system integrator for Thrive Agritech
- 03/18/22
- SpartanNash says priority of activists 'not constructive engagement'
- 03/17/22
- Food solutions company SpartanNash promotes David Sisk to Chief Customer Officer
- 03/10/22
- SpartanNash promotes David Petko to Chief Supply Chain Officer
- 03/02/22
- SpartanNash raises quarterly dividend by 5% to 21c per share
- $144.00 /
+6.595 (+4.80%) - 02/15/22
- Silvergate Capital expands Silvergate Exchange Network to include euros
- 02/09/22
- Stronghold Digital, Silvergate, Gannett mentioned as long ideas by Bill Miller
- 01/31/22
- Silvergate acquires blockchain payment network assets from Diem
- 01/18/22
- Silvergate Capital falls -19.2%
- 02/10/22
- Interpublic increases dividend from 27c to 29c, $400M share repurchase program
- 01/12/22
- Interpublic Group DXTRA CEO Andy Polansky to retire
- 11/18/21
- Interpublic Group executive chairman Michael Roth to retire
- 01/20/22
- Integral Ad Science appoints Robert Janecek as CIO
- 09/28/21
- Integral Ad Science announces brand safety solution launch for TikTok video ads
- 03/01/22
- eHealth sinks 22% to $12.05 after Q4 results miss estimates
- 03/01/22
- eHealth CEO 'implementing a number of changes'
- 03/01/22
- eHealth plans 'multi-year transformation initiative'
- 02/28/22
- eHealth appoints Roman Rariy as COO, CTO
EFSC Enterprise Financial - 10/25/21
- Enterprise Financial board raised quarterly dividend 5% to 20c per share
- 02/22/22
- Duolingo launches Haitian Creole course
- 12/14/21
- Duolingo appoints John Lilly to board of directors
- 11/18/21
- Duolingo appoints Kendra Ross as head of social impact
- 11/12/21
- Duolingo CEO: We are more of a tech company than a language company
- 03/17/22
- Dingdong falls -11.5%
- 03/16/22
- Dingdong rises 53.0%
- 03/16/22
- Dingdong rises 28.6%
- 03/16/22
- Dingdong rises 32.5%
- 03/02/22
- Check Point launches unified go-to-market organization
- 02/01/22
- Check Point acquires Spectral, terms not disclosed
- 01/17/22
- Check Point report shows DHL most imitated brand in phishing attempts in Q4
- 10/28/21
- Check Point sees 'very healthy' Q4
- 02/04/22
- Commerce Bancshares boosts quarterly dividend 6% to 26.5c
- 01/19/22
- Commerce Bancshares reports Q4 net interest margin 2.43%, down 15 bps from Q3
- 11/12/21
- Commerce Bancshares board approves 5% stock dividend
- 03/21/22
- Blend Labs falls -9.1%
- 03/08/22
- Blend Labs falls -11.3%
- 11/15/21
- Tiger Global boosts stake in Snowflake, exits TAL Education Group
- 11/11/21
- Blend Labs falls -16.7%
- 01/06/22
- Azenta names Matthew McManus as COO
- 11/16/21
- Brooks Automation to change name to Azenta, effective December 1
- 03/17/22
- AvePoint announces $150M share repurchase program
- 03/10/22
- AvePoint launches Entrust product for Microsoft 365 users
- 03/08/22
- AvePoint launches Ransomware Detection
- 02/22/22
- AvePoint enhances global partner program
- 03/08/22
- Air Products to build green liquid hydrogen production facility in Arizona
- 03/07/22
- Air Products, SARGAS to build new ASU at facility in Oman
- 02/03/22
- Air Products raises quarterly dividend 8% to $1.62 from $1.50 per share
- 12/13/21
- Air Products awards Thyssenkrupp contract to supply over 2GW electrolysis plant
- $3,237.00 /
+8.42 (+0.26%) - 03/17/22
- Amazon announces that MGM has joined Prime Video and Amazon Studios
- 03/17/22
- Smart for Life products selected by Amazon for launch in Singapore
- 03/16/22
- Senator Elizabeth Warren introduces legislation to limit 'Big Tech' mergers
- 03/15/22
- EU unconditionally approves Amazon acquisition of MGM
- 03/21/22 Argus
- Argus upgrades Interpublic Group to Buy amid increased demand, Acxiom benefits
- 03/21/22 Argus
- Interpublic Group upgraded to Buy from Hold at Argus
- 03/14/22 Barclays
- Interpublic Group downgraded to Equal Weight from Overweight at Barclays
- 01/27/22 BofA
- Interpublic Group downgraded to Underperform from Neutral at BofA
- 03/21/22 KeyBanc
- KeyBanc upgrades Duolingo to Overweight with $112 price target
- 03/21/22 KeyBanc
- Duolingo upgraded to Overweight from Sector Weight at KeyBanc
- 03/15/22 Evercore ISI
- Duolingo, XPO Logistics added to 'Best SMID 'Core' Ideas' list at Evercore ISI
- 03/04/22 Evercore ISI
- Duolingo removed from 'Tactical Outperform' list, target cut to $120 at Evercore
- 03/21/22 JPMorgan
- Air Products upgraded to Overweight from Neutral at JPMorgan
- 02/08/22 BMO Capital
- Air Products downgraded to Market Perform from Outperform at BMO Capital
- 02/07/22 Cowen
- Air Products price target lowered to $345 from $365 at Cowen
- 02/07/22 Wells Fargo
- Air Products price target lowered to $325 from $335 at Wells Fargo
- 03/21/22 Wells Fargo
- Wells Fargo upgrades Commerce Bancshares to Equal Weight, ups target to $70
- 03/21/22 Wells Fargo
- Commerce Bancshares upgraded to Equal Weight from Underweight at Wells Fargo
- 10/11/21 Jefferies
- Commerce Bancshares price target lowered to $67 from $75 at Jefferies
- 04/16/21 BofA
- Commerce Bancshares downgraded to Underperform from Neutral at BofA
- 03/21/22 Raymond James
- Integral Ad Science upgraded at Raymond James amid 'unjustified' selloff
- 03/21/22 Raymond James
- Integral Ad Science upgraded to Strong Buy from Outperform at Raymond James
- 03/17/22 Barclays
- Barclays says Meta opening up feed positive for DoubleVerify, Integral Ad
- 03/04/22 Barclays
- Integral Ad Science price target lowered to $20 from $23 at Barclays
- 03/21/22 Morgan Stanley
- Dingdong downgraded to Underweight from Overweight at Morgan Stanley
- 03/14/22 JPMorgan
- JPMorgan downgrades Dada Nexus to Neutral, prefers over smaller peer Dingdong
- 03/14/22 JPMorgan
- Dingdong price target lowered to $2.50 from $21 at JPMorgan
- 11/19/21 JPMorgan
- Dingdong initiated with an Underweight at JPMorgan
- 03/21/22 Citi
- eHealth downgraded to Neutral from Buy at Citi
- 03/03/22 Credit Suisse
- eHealth price target lowered to $16 from $31 at Credit Suisse
- 03/02/22 Craig-Hallum
- eHealth price target lowered to $15 from $33 at Craig-Hallum
- 03/02/22 Truist
- eHealth downgraded to Hold from Buy at Truist
- 03/21/22 Truist
- Truist cuts Blend Labs to Hold on lower mortgage applications, stagflation risk
- 03/21/22 Truist
- Blend Labs downgraded to Hold from Buy at Truist
- 02/14/22 Keefe Bruyette
- Blend Labs initiated with a Market Perform at Keefe Bruyette
- 01/25/22 KeyBanc
- Blend Labs price target lowered to $10 from $16 at KeyBanc
- 03/21/22 Goldman Sachs
- AvePoint downgraded to Neutral from Buy at Goldman Sachs
- 01/11/22 Cantor Fitzgerald
- AvePoint initiated with an Overweight at Cantor Fitzgerald
- 01/11/22 Cantor Fitzgerald
- AvePoint initiated with an Overweight at Cantor Fitzgerald
- 08/16/21 Cowen
- Cowen starts 'undiscovered' AvePoint with Outperform, $14.50 target
- 03/21/22 Evercore ISI
- Azenta initiated with an Outperform at Evercore ISI
- 02/09/22 Needham
- Azenta price target lowered to $115 from $155 at Needham
- 11/17/21 Stifel
- Brooks Automation price target raised to $149 from $134 at Stifel
- 11/17/21 Stephens
- Brooks Automation price target raised to $137 from $130 at Stephens
- $144.00 /
+6.595 (+4.80%) - 03/21/22 BofA
- Silvergate Capital initiated with a Buy at BofA
- 03/17/22 B. Riley
- Zions Bancorp downgraded to Neutral on valuation at B. Riley
- 02/01/22 JPMorgan
- Silvergate Capital price target lowered to $175 from $200 at JPMorgan
- 01/26/22 Keefe Bruyette
- Bloomberg report could weigh on Silvergate shares, says Keefe Bruyette
- 03/21/22 Maxim
- Urban-Gro initiated with a Buy at Maxim
- 03/21/22 Maxim
- Urban-Gro initiated with a Buy at Maxim
- 03/21/22 CL King
- SpartanNash initiated with a Neutral at CL King
- 11/15/21 Northcoast
- SpartanNash downgraded to Neutral from Buy at Northcoast
- 11/12/21 Deutsche Bank
- SpartanNash price target raised to $24 from $21 at Deutsche Bank
EFSC Enterprise Financial - 03/21/22 Boenning & Scattergood
- Enterprise Financial initiated with an Outperform at Boenning & Scattergood
- $3,237.00 /
+8.42 (+0.26%) - 03/16/22 Needham
- Needham says Netflix needs ads as streamers turn to news, sports
- 03/15/22 BWS Financial
- BWS drops coverage of PLx Pharma, says off Amazon again
- 03/10/22 Deutsche Bank
- Amazon.com initiated with a Buy at Deutsche Bank
- 03/21/22 Piper Sandler
- Check Point downgraded to Underweight from Neutral at Piper Sandler
- 03/17/22 Deutsche Bank
- Check Point price target raised to $160 from $154 at Deutsche Bank
- 03/10/22 Cowen
- Check Point price target raised to $164 from $142 at Cowen
- 02/16/22 BMO Capital
- Check Point upgraded to Outperform from Market Perform at BMO Capital
- 01/05/22
- Urban-Gro sees 2021 revenue $62M, one est. $64.67M.
- 02/24/22
- SpartanNash sees 2022 adjusted EPS $2.10-$2.25, consensus $1.91
- 02/24/22
- SpartanNash reports Q4 adjusted EPS 18c, consensus 23c
- 11/10/21
- SpartanNash backs FY21 adjusted EPS view $1.70-$1.80, consensus $1.78
- 11/10/21
- SpartanNash reports Q3 adjusted EPS 43c, consensus 41c
- $144.00 /
+6.595 (+4.80%) - 01/18/22
- Silvergate Capital reports Q4 EPS 66c, consensus 72c
- 10/19/21
- Silvergate Capital reports Q3 EPS 88c, consensus 71c
- 02/10/22
- Interpublic Group reports Q4 adjusted EPS 82c, consensus 81c
- 02/09/22
- Notable companies reporting before tomorrow's open
- 10/21/21
- Interpublic Group raises 2021 organic growth view to 11% from 9%-10%
- 03/03/22
- Integral Ad Science sees FY22 revenue $416M-$424M, consensus $404.37M
- 03/03/22
- Integral Ad Science sees Q1 revenue $85M-$87M, consensus $84.41M
- 03/03/22
- Integral Ad Science reports Q4 EPS (3c), consensus (1c)
- 11/10/21
- Integral Ad Science sees 2021 revenue $315M-$317M, consensus $309.59M
- 03/01/22
- eHealth sees FY22 revenue $448M-$470M, consensus $591.53M
- 03/01/22
- eHealth reports Q4 adjusted EPS 49c, consensus 94c
- 11/08/21
- eHealth lowers FY21 non-GAAP EPS view to (45c)-($1.13) from $$2.77-$3.26
- 11/08/21
- eHealth reports Q3 non-GAAP EPS ($1.78), consensus ($1.02)
EFSC Enterprise Financial - 01/24/22
- Enterprise Financial reports Q4 adjusted EPS $1.23, consensus $1.19
- 10/25/21
- Enterprise Financial reports Q3 adjusted EPS $1.27, consensus $1.00
- 10/25/21
- Enterprise Financial reports Q3 EPS 38c, consensus $1.00
- 03/03/22
- Duolingo reports Q4 EPS (46c), consensus (68c)
- 11/10/21
- Duolingo sees Q4 revenue $66.5M-$69.5M, consensus $65.65M
- 11/10/21
- Duolingo reports Q3 EPS (98c), consensus (95c)
- 02/03/22
- Check Point sees FY22 EPS $6.90-$7.50, consensus $7.34
- 02/03/22
- Check Point sees Q1 EPS $1.48-$1.58, consensus $1.61
- 02/03/22
- Check Point reports Q4 EPS $2.25, consensus $2.12
- 10/28/21
- Check Point sees FY21 EPS $6.81-$7.01, consensus $6.78
- 01/19/22
- Commerce Bancshares reports Q4 EPS 94c, consensus 94c
- 10/19/21
- Commerce Bancshares reports Q3 EPS $1.05, consensus 99c
- 11/10/21
- Blend Labs raises FY21 pro forma revenue view to $376M-$386M, consensus $369.75M
- 11/10/21
- Blend Labs reports Q3 GAAP EPS (38c) vs. (38c) a year ago
- 02/08/22
- Azenta sees Q2 non-GAAP EPS 7c-15c, consensus 11c
- 02/08/22
- Azenta reports Q1 non-GAAP EPS 12c, consensus 8c
- 03/17/22
- AvePoint sees FY22 revenue $236M-$242M, consensus $254.67M
- 03/17/22
- AvePoint sees Q1 revenue $48M-$49M, consensus $50.53M
- 03/17/22
- AvePoint reports Q4 EPS (4c), consensus 0c
- 11/15/21
- AvePoint sees 2021 revenue $194.4M-$196.4M, consensus $193.89M
- 02/04/22
- Air Products backs FY22 adjusted EPS view $10.20-$10.40, consensus $10.36
- 02/04/22
- Air Products sees Q2 adjusted EPS $2.30-$2.40, consensus $2.52
- 02/04/22
- Air Products reports Q1 adjusted EPS $2.52, consensus $2.51
- 11/04/21
- Air Products sees FY22 adjusted EPS $10.20-$10.40, consensus $10.68
- $3,237.00 /
+8.42 (+0.26%) - 02/03/22
- Amazon sees Q1 revenue $112B-$117B, consensus $120.11B
- 02/03/22
- Amazon reports Q4 EPS $27.75 with gains vs. $14.09 a year ago
- 02/03/22
- Notable companies reporting after market close
- 11/10/21
- Affirm sees fiscal 2022 revenue $1.225B-$1.25B, consensus $1.20B
|
Initiation
|
Evercore ISI analyst… Evercore ISI analyst Vijay Kumar initiated coverage of Azenta with an Outperform rating and $100 price target. With the recent sale of its semi business and the company changing its name to "Azenta" from "Brooks Automation," the company has transitioned from an "industrial/cyclical bent" to pure play life sciences with 100% of its revenues now being life sciences, said Kumar, who sees Azenta offering a "compelling" superior revenue growth outlook with 50% EPS compound annual growth rate potential. ShowHide Related Items >><< - 01/06/22
- Azenta names Matthew McManus as COO
- 11/16/21
- Brooks Automation to change name to Azenta, effective December 1
- 02/09/22 Needham
- Azenta price target lowered to $115 from $155 at Needham
- 11/17/21 Stifel
- Brooks Automation price target raised to $149 from $134 at Stifel
- 11/17/21 Stephens
- Brooks Automation price target raised to $137 from $130 at Stephens
- 02/08/22
- Azenta sees Q2 non-GAAP EPS 7c-15c, consensus 11c
- 02/08/22
- Azenta reports Q1 non-GAAP EPS 12c, consensus 8c
- 12/01/21
- Thirteen new option listings and one option delisting on December 1st
|